Oxaliplatin – Uses, Dosage, Side Effects, Interaction Oxaliplatin is an intravenously administered platinum-containing alkylating agent which is used for the treatment of advanced colorectal cancer. Oxaliplatin therapy is associated with a low rate of transient serum aminotransferase elevations but is commonly associated with sinusoidal and vascular injury to the liver which can lead to sinusoidal obstruction syndrome and to nodular regenerative hyperplasia with noncirrhotic portal hypertension. Oxaliplatin is an organoplatinum complex in which the platinum atom is complexed with 1,2-diaminocyclohexane (DACH) and with an oxalate ligand as a ‘leaving group.’ A ‘leaving group’ is an atom or a group of atoms that is displaced as a stable species taking with it the bonding electrons. After the displacement of the labile oxalate, ligand leaving group, active oxaliplatin derivatives, such as monocoque and diaquo DACH platinum, alkylate macromolecules, forming both inter- and intra-strand platinum-DNA crosslinks, which result in inhibition of DNA replication and transcription and cell-cycle nonspecific cytotoxicity. The DACH side chain appears to inhibit alkylating-agent resistance. (NCI04) Oxaliplatin is a platinum-based chemotherapy drug in the same family as cisplatin and carboplatin. It is typically administered in combination with fluorouracil and leucovorin in a combination known as Folfox for the treatment of colorectal cancer. Compared to cisplatin the two amine groups are replaced by cyclohexyl diamine for improved antitumor activity. The chlorine ligands are replaced by the oxalate bidentate derived from oxalic acid in order to improve water solubility. Oxaliplatin is marketed by Sanofi-Aventis under the trademark Eloxatin. Oxaliplatin is a platinum coordination entity that is a commonly used chemotherapeutic drug for the treatment of colorectal cancer. It has a role as an antineoplastic agent and a mutagen. An organoplatinum complex in which the platinum atom is complexed with 1,2-diaminocyclohexane, and with an oxalate ligand which is displaced to yield active oxaliplatin derivatives. These derivatives form inter and intra-strand DNA crosslinks that inhibit DNA replication and transcription. Oxaliplatin is an antineoplastic agent that is often administered with FLUOROURACIL and FOLINIC ACID in the treatment of metastatic COLORECTAL NEOPLASMS. Mechanism of Action Oxaliplatin undergoes nonenzymatic conversion to active derivatives via displacement of the labile oxalate ligand. Several transient reactive species are formed, including Monaco and diaquo DACH platinum, which covalently bind with macromolecules. After activation, oxaliplatin binds preferentially to the guanine and cytosine moieties of DNA, leading to cross-linking of DNA, thus inhibiting DNA synthesis and transcription. Cytotoxicity is cell-cycle nonspecific. Oxaliplatin selectively inhibits the synthesis of deoxyribonucleic acid (DNA). The guanine and cytosine content correlates with the degree of Oxaliplatin-induced cross-linking. At high concentrations of the drug, cellular RNA and protein synthesis are also suppressed. or The compound features a square planar platinum(II) center. In contrast to other drugs of the platinum-based antineoplastic class of drugs cisplatin and carboplatin, oxaliplatin features the bidentate ligand trans-1,2-diaminocyclohexane in place of the two monodentate ammine ligands. It also features a bidentate oxalate group. The three-dimensional structure of the molecule has been elucidated by X-ray crystallography, although the presence of pseudosymmetry in the crystal structure has caused confusion in its interpretation. According to in vivo studies, oxaliplatin fights carcinoma of the colon through non-targeted cytotoxic effects. Like other platinum compounds, its cytotoxicity is thought to result from the inhibition of DNA synthesis in cells. In particular, oxaliplatin forms both inter- and intra-strand cross-links in DNA,[rx] which prevent DNA replication and transcription, causing cell death. Indications Used in combination with infusional 5-FU/LV, is indicated for the treatment of advanced carcinoma of the colon or rectum and for adjuvant treatment of stage III colon cancer patients who have undergone complete resection of the primary tumor. Used in combination with infusional 5-FU/LV, is indicated for the treatment of advanced carcinoma of the colon or rectum and for adjuvant treatment of stage III colon cancer patients who have undergone complete resection of the primary tumor. Oxaliplatin is approved to be used with fluorouracil and leucovorin calcium to treat: Colorectal cancer that is advanced Stage III colon cancer. It is used after surgery to remove cancer. Advanced Colorectal Cancer Stage III Colon Cancer Contraindication low amount of magnesium in the blood low amount of potassium in the blood anemia decreased blood platelets low levels of a type of white blood cell called neutrophils a painful condition that affects the nerves in the legs and arms called peripheral neuropathy abnormal EKG with QT changes from birth a type of inflammation of the lung called interstitial pneumonitis a condition where there is formation of fibrous tissue in the lung called pulmonary fibrosis abnormal liver function tests pregnancy a patient who is producing milk and breastfeeding muscle pain or tenderness with increase creatine kinase a type of brain disorder called posterior reversible encephalopathy syndrome chronic kidney disease stage 4 (severe) chronic kidney disease stage 5 (failure) Dosage Strengths: 5 mg/mL; 50 mg; 100 mg Colorectal Cancer 85 mg/m2 via IV infusion over 120 minutes every 2 weeks; administer in combination with infusional 5-fluorouracil and leucovorin. Duration of Therapy Adjuvant Treatment of Stage III Colon Cancer: Total of 6 months (12 cycles) Treatment of Advanced Colorectal Cancer: Until disease progression or unacceptable toxicity Premedication with antiemetics, including 5-HT3 blockers with or without dexamethasone, is recommended. Consult the manufacturer product information for 5-fluorouracil and leucovorin dosing recommendations. Uses In combination with infusional 5-fluorouracil and leucovorin: Adjuvant treatment of Stage III colon cancer in patients who have undergone complete resection of the primary tumor. Treatment of advanced colorectal cancer. Renal Dose Adjustments Mild to Moderate Renal Impairment (CrCl 30 to 80 mL/min): No adjustment recommended. Severe Renal Impairment (CrCl less than 30 mL/min): Reduce dose to 65 mg/m2. Dose Adjustments ACUTE TOXICITIES: Consider prolonging the infusion time for this drug from 2 hours to 6 hours. AFTER RECOVERY FROM GRADE 3/4 GASTROINTESTINAL TOXICITY (DESPITE PROPHYLACTIC TREATMENT) Adjuvant Treatment of Stage III Colon Cancer: 75 mg/m2 Treatment of Advanced Colorectal Cancer: 65 mg/m2 GRADE 4 NEUTROPENIA, FEBRILE NEUTROPENIA, OR GRADE 3/4 THROMBOCYTOPENIA: Reduce the dose and delay the next dose until neutrophils 1.5 x 10(9)/L or greater and platelets 75 x 10(9)/L or greater. Adjuvant Treatment of Stage III Colon Cancer: 75 mg/m2 Treatment of Advanced Colorectal Cancer: 65 mg/m2 NEUROSENSORY EVENTS GRADE 2: Consider reducing the dose. Adjuvant Treatment of Stage III Colon Cancer: 75 mg/m2 Treatment of Advanced Colorectal Cancer: 65 mg/m2 GRADE 3: Consider treatment discontinuation (for both indications). Administration Advice Dilute this drug before administration; consult the manufacturer’s product information for dilution instructions. Consult the manufacturer’s product information for infusion instructions. Do not use needles or IV administration sets containing aluminum parts since aluminum has been reported to cause the degradation of platinum compounds. Immediately discontinue drug administration and initiate usual local symptomatic treatment in the event of extravasation. Prior to administration, visually inspect for particulate matter and discoloration and discard if present. Prior to subsequent therapy cycles, evaluate patients for clinical toxicities and recommended laboratory tests. The administration of this drug does not require prehydration. Storage Requirements After dilution, the shelf life of this drug is 6 hours at room temperature (20 to 25 degrees Celsius/68 to 77 degrees Fahrenheit) or up to 24 hours under refrigeration (2 to 8 degrees Celsius/36 to 46 degrees Fahrenheit). Retain this drug in its original package until the time of use. Do not freeze and protect from light; however, the final diluted drug does not need protection from light. Reconstitution/Preparation Techniques Exercise care and use gloves when handling this drug. If a solution of this drug contacts the skin or mucous membranes, wash the skin immediately with soap and water and flush the mucous membranes thoroughly with water. IV Compatibility Do not mix or administer this drug simultaneously through the same infusion line with alkaline medications or media (e.g., basic solutions of 5-fluorouracil, folinic acid preparations containing trometamol, trometamol salts of other active substances) as alkaline products will adversely affect the stability of this drug. Reconstitution/final dilution of this drug should not be performed with saline or other solutions containing chloride ions (including sodium, calcium, or potassium chloride). Consult the manufacturer product information for additional IV compatibilities and incompatibilities. General Overdosage: No known antidote. Monitoring Monitor a full blood count with white cell differential, hemoglobin, platelet count, and blood chemistries (including ALT, AST, bilirubin, and creatinine) prior to treatment initiation and before each subsequent treatment cycle. Monitor neurological toxicity; perform a neurological examination before each administration and periodically thereafter. Patient Advice Avoid potentially dangerous activities such as driving and operating machinery until you know how this drug affects you. Side Effects The Most Common Numbness, burning, or tingling in the fingers, toes, hands, feet, mouth, or throat Neurotoxicity leads to chemotherapy-induced peripheral neuropathy, a progressive, enduring, and often irreversible tingling numbness, intense pain, and hypersensitivity to cold, beginning in the hands and feet and sometimes involving the arms and legs, often with deficits in proprioception. This chronic neuropathy may also be preceded by a transient acute neuropathy occurring at the time of infusion and associated with the excitation of voltage-gated Na+ channels. Fatigue Nausea, vomiting, or diarrhea Neutropenia (low number of a type of white blood cells) Ototoxicity (hearing loss) Extravasation if oxaliplatin leaks from the infusion vein may cause severe damage to the connective tissues. Hypokalemia (low blood potassium), which is more common in women than men Persistent hiccups pain in the hands or feet increased sensitivity, especially to cold decreased sense of touch nausea vomiting diarrhea constipation gas stomach pain heartburn sores in the mouth loss of appetite change in the ability to taste food weight gain or loss hiccups dry mouth muscle, back, or joint pain tiredness anxiety depression difficulty falling asleep or staying asleep hair loss dry skin redness or peeling of the skin on the hands and feet sweating flushing More Common stumbling or loss of balance when walking difficulty with everyday activities such as writing or fastening buttons difficulty speaking strange feeling in the tongue tightening of the jaw chest pain or pressure cough shortness of breath sore throat, fever, chills, and other signs of infection pain, redness, or swelling in the place where oxaliplatin was injected pain when urinating decreased urination unusual bruising or bleeding nosebleed blood in urine vomit that is bloody or looks like coffee grounds bright red blood in stool black and tarry stools pale skin weakness problems with vision swelling of the arms, hands, feet, ankles, or lower legs Rare chills or shivering burning or pain on urination pain on swallowing redness or swelling at the intravenous site sore throat persistent diarrhea cough that brings up mucus Leukemia, a form of blood cancer, has been reported in patients after taking oxaliplatin in combination with certain other medicines. Lung problems. Oxaliplatin can cause lung problems that may lead to death. Tell your doctor right away if you get any of the following symptoms as these may be indicators of serious lung disease: shortness of breath, cough, wheezing Liver problems (hepatotoxicity). Your doctor will do blood tests to check your liver when you start receiving oxaliplatin, and before each treatment course as needed. Heart problems. Oxaliplatin can cause heart problems that have led to death. Your doctor may do blood and heart tests during treatment with oxaliplatin if you have certain heart problems. If you faint (lose consciousness) or have an irregular heartbeat or chest pain during treatment with oxaliplatin, get medical help right away as this may be a sign of a serious heart condition. Muscle problems. Oxaliplatin can cause muscle damage (rhabdomyolysis) which can lead to death. Tell your doctor right away if you have muscle pain and swelling, along with weakness, fever, or red-brown urine. Harm to an unborn baby. Bleeding problems (hemorrhage). Oxaliplatin when used with fluorouracil and leucovorin can cause bleeding problems (hemorrhage) that can lead to death. Your risk of bleeding may increase if you are also taking a blood thinner medicine. Tell your healthcare provider if you have any signs or symptoms of bleeding, including: blood in your stools or black stools (looks like tar) pink or brown urine unexpected bleeding, or bleeding that is severe or you cannot control vomit blood or vomit that looks like coffee grounds cough up blood or blood clots increased bruising dizziness weakness confusion changes in speech headache that lasts a long time Drug Interaction DRUG INTERACTION Abatacept The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Abatacept. Abciximab The risk or severity of bleeding can be increased when Abciximab is combined with Oxaliplatin. Abemaciclib Abemaciclib may decrease the excretion rate of Oxaliplatin which could result in a higher serum level. Acenocoumarol The risk or severity of bleeding can be increased when Acenocoumarol is combined with Oxaliplatin. Acetylsalicylic acid The risk or severity of bleeding can be increased when Acetylsalicylic acid is combined with Oxaliplatin. Acrivastine The risk or severity of QTc prolongation can be increased when Acrivastine is combined with Oxaliplatin. Adalimumab The risk or severity of adverse effects can be increased when Adalimumab is combined with Oxaliplatin. Adenosine The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Adenosine. Adenovirus The risk or severity of infection can be increased when Adenovirus type 7 vaccine live is combined with Oxaliplatin. Afatinib Afatinib may decrease the excretion rate of Oxaliplatin which could result in a higher serum level. Ajmaline The risk or severity of QTc prolongation can be increased when Ajmaline is combined with Oxaliplatin. Aldesleukin The risk or severity of adverse effects can be increased when Aldesleukin is combined with Oxaliplatin. Alectinib Alectinib may decrease the excretion rate of Oxaliplatin which could result in a higher serum level. Alefacept The risk or severity of adverse effects can be increased when Alefacept is combined with Oxaliplatin. Alemtuzumab The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Oxaliplatin. Alfuzosin The risk or severity of QTc prolongation can be increased when Alfuzosin is combined with Oxaliplatin. Alimemazine The risk or severity of QTc prolongation can be increased when Alimemazine is combined with Oxaliplatin. Allogeneic The therapeutic efficacy of Allogeneic processed thymus tissue can be decreased when used in combination with Oxaliplatin. Allopurinol The risk or severity of adverse effects can be increased when Allopurinol is combined with Oxaliplatin. Alteplase The risk or severity of bleeding can be increased when Alteplase is combined with Oxaliplatin. Altretamine The risk or severity of adverse effects can be increased when Altretamine is combined with Oxaliplatin. Amantadine The serum concentration of Oxaliplatin can be increased when it is combined with Amantadine. Amifampridine The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Amifampridine. Amiloride The serum concentration of Oxaliplatin can be increased when it is combined with Amiloride. Aminohippuric acid The serum concentration of Oxaliplatin can be increased when it is combined with Aminohippuric acid. Amiodarone The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Amiodarone. Amisulpride The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Amisulpride. Amitriptyline The risk or severity of QTc prolongation can be increased when Amitriptyline is combined with Oxaliplatin. Amodiaquine The risk or severity of QTc prolongation can be increased when Amodiaquine is combined with Oxaliplatin. Amoxapine The risk or severity of QTc prolongation can be increased when Amoxapine is combined with Oxaliplatin. Amsacrine The risk or severity of adverse effects can be increased when Amsacrine is combined with Oxaliplatin. Anagrelide The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Anagrelide. Anakinra The risk or severity of adverse effects can be increased when Anakinra is combined with Oxaliplatin. Ancrod The risk or severity of bleeding can be increased when Ancrod is combined with Oxaliplatin. Anifrolumab The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Anifrolumab. Anistreplase The risk or severity of bleeding can be increased when Anistreplase is combined with Oxaliplatin. Antazoline The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Antazoline. Anthrax immune The therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Oxaliplatin. Anthrax vaccine The risk or severity of infection can be increased when Anthrax vaccine is combined with Oxaliplatin. Antilymphocyte The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Antilymphocyte immunoglobulin (horse). Antithrombin Alfa The risk or severity of bleeding can be increased when Antithrombin Alfa is combined with Oxaliplatin. Antithrombin III human The risk or severity of bleeding can be increased when Antithrombin III human is combined with Oxaliplatin. Antithymocyte The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Oxaliplatin. Apalutamide The serum concentration of Oxaliplatin can be increased when it is combined with Apalutamide. Apixaban The risk or severity of bleeding can be increased when Apixaban is combined with Oxaliplatin. Apomorphine The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Oxaliplatin. Apremilast The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Apremilast. Ardeparin The risk or severity of bleeding can be increased when Ardeparin is combined with Oxaliplatin. Arformoterol The risk or severity of QTc prolongation can be increased when Arformoterol is combined with Oxaliplatin. Argatroban The risk or severity of bleeding can be increased when Argatroban is combined with Oxaliplatin. Aripiprazole The risk or severity of QTc prolongation can be increased when Aripiprazole is combined with Oxaliplatin. Aripiprazole lauroxil The risk or severity of QTc prolongation can be increased when Aripiprazole lauroxil is combined with Oxaliplatin. Arsenic trioxide The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Arsenic trioxide. Artemether The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Artemether. Articaine The risk or severity of methemoglobinemia can be increased when Oxaliplatin is combined with Articaine. Asenapine The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Asenapine. Astemizole The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Astemizole. COVID-19 Vaccine The therapeutic efficacy of AstraZeneca COVID-19 Vaccine can be decreased when used in combination with Oxaliplatin. Atazanavir The risk or severity of QTc prolongation can be increased when Atazanavir is combined with Oxaliplatin. Atomoxetine The risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Oxaliplatin. Atropine The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Atropine. Avanafil Avanafil may decrease the excretion rate of Oxaliplatin which could result in a higher serum level. Avatrombopag Avatrombopag may decrease the excretion rate of Oxaliplatin which could result in a higher serum level. Azacitidine The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Azacitidine. Azatadine The risk or severity of QTc prolongation can be increased when Azatadine is combined with Oxaliplatin. Azathioprine The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Azathioprine. Azithromycin The risk or severity of QTc prolongation can be increased when Azithromycin is combined with Oxaliplatin. Bacillus connaught The risk or severity of infection can be increased when Bacillus calmette-guerin substrain connaught live antigen is combined with Oxaliplatin. Guerin substrain russian The therapeutic efficacy of Bacillus calmette-guerin substrain russian BCG-I live antigen can be decreased when used in combination with Oxaliplatin. Bacillus calmette The risk or severity of infection can be increased when Bacillus calmette-guerin substrain tice live antigen is combined with Oxaliplatin. Baricitinib The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Baricitinib. Basiliximab The risk or severity of adverse effects can be increased when Basiliximab is combined with Oxaliplatin. BCG vaccine The risk or severity of infection can be increased when BCG vaccine is combined with Oxaliplatin. Beclomethasone The risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Oxaliplatin. Bedaquiline The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Bedaquiline. Belatacept The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Belatacept. Belimumab The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Belimumab. Belinostat The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Belinostat. Belumosudil The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Belumosudil. Bemiparin The risk or severity of bleeding can be increased when Bemiparin is combined with Oxaliplatin. Bendamustine The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Bendamustine. Bendroflumethiazide The risk or severity of neutropenia and thrombocytopenia can be increased when Bendroflumethiazide is combined with Oxaliplatin. Benzatropine The risk or severity of QTc prolongation can be increased when Benzatropine is combined with Oxaliplatin. Benzocaine The risk or severity of methemoglobinemia can be increased when Oxaliplatin is combined with Benzocaine. Benzthiazide The risk or severity of neutropenia and thrombocytopenia can be increased when Benzthiazide is combined with Oxaliplatin. Benzyl alcohol The risk or severity of methemoglobinemia can be increased when Oxaliplatin is combined with Benzyl alcohol. Bepridil The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Bepridil. Berotralstat The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Berotralstat. Betamethasone The risk or severity of adverse effects can be increased when Betamethasone is combined with Oxaliplatin. Betrixaban The risk or severity of bleeding can be increased when Betrixaban is combined with Oxaliplatin. Bexarotene The risk or severity of adverse effects can be increased when Bexarotene is combined with Oxaliplatin. Bilastine The risk or severity of QTc prolongation can be increased when Bilastine is combined with Oxaliplatin. Bimekizumab The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Bimekizumab. Bivalirudin The risk or severity of bleeding can be increased when Bivalirudin is combined with Oxaliplatin. Bleomycin The risk or severity of adverse effects can be increased when Bleomycin is combined with Oxaliplatin. Blinatumomab The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Blinatumomab. Bordetella The therapeutic efficacy of Bordetella pertussis toxoid antigen (formaldehyde, glutaraldehyde inactivated) can be decreased when used in combination with Oxaliplatin. Bortezomib The risk or severity of adverse effects can be increased when Bortezomib is combined with Oxaliplatin. Bosutinib The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Bosutinib. Brentuximab vedotin The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Brentuximab vedotin. Desipramine The serum concentration of Oxaliplatin can be increased when it is combined with Desipramine. Desirudin The risk or severity of bleeding can be increased when Desirudin is combined with Oxaliplatin. Desloratadine The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Desloratadine. Desoximetasone The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Desoximetasone. Deucravacitinib The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Deucravacitinib. Deutetrabenazine The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Deutetrabenazine. Dexamethasone The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Dexamethasone. Dexamethasone acetate Dexamethasone acetate may decrease the excretion rate of Oxaliplatin which could result in a higher serum level. Dexbrompheniramine The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Oxaliplatin. Dexchlorpheniramine The serum concentration of Oxaliplatin can be increased when it is combined with Dexchlorpheniramine maleate. Dexrazoxane The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Oxaliplatin. Dextran The risk or severity of bleeding can be increased when Dextran is combined with Oxaliplatin. Dicoumarol The risk or severity of bleeding can be increased when Dicoumarol is combined with Oxaliplatin. Diethylstilbestrol Diethylstilbestrol may decrease the excretion rate of Oxaliplatin which could result in a higher serum level. Difluocortolone The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Difluocortolone. Digitoxin The risk or severity of QTc prolongation can be increased when Digitoxin is combined with Oxaliplatin. Digoxin The risk or severity of QTc prolongation can be increased when Digoxin is combined with Oxaliplatin. Diltiazem The risk or severity of QTc prolongation can be increased when Diltiazem is combined with Oxaliplatin. Dimenhydrinate The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Dimenhydrinate. Dimethyl fumarate The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Dimethyl fumarate. Dinoprostone The serum concentration of Oxaliplatin can be increased when it is combined with Dinoprostone. Dinutuximab The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Dinutuximab. Diphenhydramine The risk or severity of methemoglobinemia can be increased when Oxaliplatin is combined with Diphenhydramine. Dipyridamole The risk or severity of bleeding can be increased when Dipyridamole is combined with Oxaliplatin. Diroximel fumarate The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Diroximel fumarate. Disopyramide The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Disopyramide. Disulfiram The risk or severity of QTc prolongation can be increased when Disulfiram is combined with Oxaliplatin. Docetaxel The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Docetaxel. Dofetilide The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Dofetilide. Dolasetron The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Dolasetron. Dolutegravir The serum concentration of Oxaliplatin can be increased when it is combined with Dolutegravir. Domperidone The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Domperidone. Dopamine The serum concentration of Oxaliplatin can be increased when it is combined with Dopamine. Dosulepin The risk or severity of QTc prolongation can be increased when Dosulepin is combined with Oxaliplatin. Doxepin The risk or severity of QTc prolongation can be increased when Doxepin is combined with Oxaliplatin. Doxorubicin The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Doxorubicin. Doxylamine The risk or severity of QTc prolongation can be increased when Doxylamine is combined with Oxaliplatin. Dronedarone The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Dronedarone. Droperidol The risk or severity of QTc prolongation can be increased when Droperidol is combined with Oxaliplatin. Drotrecogin alfa The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Oxaliplatin. Dyclonine The risk or severity of methemoglobinemia can be increased when Oxaliplatin is combined with Dyclonine. Ebastine The risk or severity of QTc prolongation can be increased when Ebastine is combined with Oxaliplatin. Ebola Zaire The therapeutic efficacy of Ebola Zaire vaccine (live, attenuated) can be decreased when used in combination with Oxaliplatin. Eculizumab The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Eculizumab. Edetic acid The risk or severity of bleeding can be increased when Edetic acid is combined with Oxaliplatin. Edoxaban The risk or severity of bleeding can be increased when Edoxaban is combined with Oxaliplatin. Efalizumab The risk or severity of adverse effects can be increased when Efalizumab is combined with Oxaliplatin. Efavirenz The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Efavirenz. Elbasvir Elbasvir may decrease the excretion rate of Oxaliplatin which could result in a higher serum level. Eliglustat The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Eliglustat. Eltrombopag Eltrombopag may decrease the excretion rate of Oxaliplatin which could result in a higher serum level. Emapalumab The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Emapalumab. Emedastine The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Emedastine. Enasidenib The serum concentration of Oxaliplatin can be increased when it is combined with Enasidenib. Encainide The risk or severity of QTc prolongation can be increased when Encainide is combined with Oxaliplatin. Encorafenib The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Encorafenib. Enoxacin The risk or severity of QTc prolongation can be increased when Enoxacin is combined with Oxaliplatin. Enoxaparin The risk or severity of bleeding can be increased when Enoxaparin is combined with Oxaliplatin. Entrectinib The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Entrectinib. Epinastine The risk or severity of QTc prolongation can be increased when Epinastine is combined with Oxaliplatin. Epinephrine The serum concentration of Oxaliplatin can be increased when it is combined with Epinephrine. Epirubicin The risk or severity of adverse effects can be increased when Epirubicin is combined with Oxaliplatin. Epoprostenol The risk or severity of bleeding can be increased when Epoprostenol is combined with Oxaliplatin. Eptifibatide The risk or severity of bleeding can be increased when Eptifibatide is combined with Oxaliplatin. Erdafitinib The serum concentration of Oxaliplatin can be increased when it is combined with Erdafitinib. Eribulin The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Eribulin. Erlotinib The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Erlotinib. Erythromycin The risk or severity of QTc prolongation can be increased when Erythromycin is combined with Oxaliplatin. Erythropoietin The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Oxaliplatin. Escitalopram The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Escitalopram. Esmolol The risk or severity of QTc prolongation can be increased when Esmolol is combined with Oxaliplatin. Estradiol The serum concentration of Oxaliplatin can be increased when it is combined with Estradiol. Estradiol acetate The serum concentration of Oxaliplatin can be increased when it is combined with Estradiol acetate. Estradiol benzoate The serum concentration of Oxaliplatin can be increased when it is combined with Estradiol benzoate. Estradiol cypionate The serum concentration of Oxaliplatin can be increased when it is combined with Estradiol cypionate. Estradiol dienanthate The serum concentration of Oxaliplatin can be increased when it is combined with Estradiol dienanthate. Estradiol valerate The serum concentration of Oxaliplatin can be increased when it is combined with Estradiol valerate. Estramustine The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Estramustine. Etanercept The risk or severity of adverse effects can be increased when Etanercept is combined with Oxaliplatin. Ethosuximide The risk or severity of QTc prolongation can be increased when Ethosuximide is combined with Oxaliplatin. Ethyl chloride The risk or severity of methemoglobinemia can be increased when Oxaliplatin is combined with Ethyl chloride. Etidocaine The risk or severity of methemoglobinemia can be increased when Oxaliplatin is combined with Etidocaine. Etoposide The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Etoposide. Everolimus The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Everolimus. Ezogabine The risk or severity of QTc prolongation can be increased when Ezogabine is combined with Oxaliplatin. Famotidine The serum concentration of Oxaliplatin can be increased when it is combined with Famotidine. Famtozinameran The therapeutic efficacy of Famtozinameran can be decreased when used in combination with Oxaliplatin. Febuxostat The excretion of Oxaliplatin can be decreased when combined with Febuxostat. Fedratinib Fedratinib may decrease the excretion rate of Oxaliplatin which could result in a higher serum level. Felbamate The risk or severity of QTc prolongation can be increased when Felbamate is combined with Oxaliplatin. Felodipine The risk or severity of QTc prolongation can be increased when Felodipine is combined with Oxaliplatin. Fexinidazole The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Fexinidazole. Filgotinib The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Filgotinib. Fingolimod Oxaliplatin may increase the immunosuppressive activities of Fingolimod. Flecainide The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Flecainide. Floxuridine The risk or severity of adverse effects can be increased when Floxuridine is combined with Oxaliplatin. Fluconazole The risk or severity of QTc prolongation can be increased when Fluconazole is combined with Oxaliplatin. Flucytosine The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Flucytosine. Fludarabine The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Fludarabine. Fludrocortisone The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Fludrocortisone. Fluindione The risk or severity of bleeding can be increased when Fluindione is combined with Oxaliplatin. Flunisolide The risk or severity of adverse effects can be increased when Flunisolide is combined with Oxaliplatin. Fluocinolone acetonide The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Fluocinolone acetonide. Fluocinonide The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Fluocinonide. Fluocortolone The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Fluocortolone. Fluorometholone The risk or severity of adverse effects can be increased when Fluorometholone is combined with Oxaliplatin. Fluorouracil The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Fluorouracil. Fluoxetine The risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Oxaliplatin. Flupentixol The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Flupentixol. Fluprednisolone The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Fluprednisolone. Flurazepam The serum concentration of Oxaliplatin can be increased when it is combined with Flurazepam. Fluspirilene The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Fluspirilene. Fluticasone The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Fluticasone. Fluticasone furoate The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Fluticasone furoate. Fluticasone propionate The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Fluticasone propionate. Fondaparinux The risk or severity of bleeding can be increased when Fondaparinux is combined with Oxaliplatin. Formoterol The risk or severity of QTc prolongation can be increased when Formoterol is combined with Oxaliplatin. Foscarnet The risk or severity of QTc prolongation can be increased when Foscarnet is combined with Oxaliplatin. Fosphenytoin Oxaliplatin can cause a decrease in the absorption of Fosphenytoin resulting in a reduced serum concentration and potentially a decrease in efficacy. Fostamatinib Fostamatinib may decrease the excretion rate of Oxaliplatin which could result in a higher serum level. Fostemsavir Fostemsavir may decrease the excretion rate of Oxaliplatin which could result in a higher serum level. Fusidic acid Fusidic acid may decrease the excretion rate of Oxaliplatin which could result in a higher serum level. Gadobenic acid The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Gadobenic acid. Galantamine The risk or severity of QTc prolongation can be increased when Galantamine is combined with Oxaliplatin. Gallium nitrate The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Gallium nitrate. Gatifloxacin The risk or severity of QTc prolongation can be increased when Gatifloxacin is combined with Oxaliplatin. Gefitinib Gefitinib may decrease the excretion rate of Oxaliplatin which could result in a higher serum level. Gemcitabine The risk or severity of adverse effects can be increased when Gemcitabine is combined with Oxaliplatin. Gemifloxacin The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Gemifloxacin. Gemtuzumab ozogamicin The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Oxaliplatin. Gilteritinib The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Gilteritinib. Glasdegib The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Glasdegib. Glatiramer The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Glatiramer. Glecaprevir Glecaprevir may decrease the excretion rate of Oxaliplatin which could result in a higher serum level. Golimumab The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Golimumab. Goserelin The risk or severity of QTc prolongation can be increased when Goserelin is combined with Oxaliplatin. Granisetron The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Granisetron. Grazoprevir Grazoprevir may decrease the excretion rate of Oxaliplatin which could result in a higher serum level. Grepafloxacin The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Grepafloxacin. Guanidine The serum concentration of Oxaliplatin can be increased when it is combined with Guanidine. Guselkumab The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Guselkumab. Haemophilus The therapeutic efficacy of Haemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen can be decreased when used in combination with Oxaliplatin. Halofantrine The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Halofantrine. Haloperidol The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Haloperidol. Heparin The risk or severity of bleeding can be increased when Heparin is combined with Oxaliplatin. Hepatitis A Vaccine The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Oxaliplatin. Hepatitis B Vaccine The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Oxaliplatin. Histamine The serum concentration of Oxaliplatin can be increased when it is combined with Histamine. Histrelin The risk or severity of QTc prolongation can be increased when Histrelin is combined with Oxaliplatin. Human adenovirus The risk or severity of infection can be increased when Human adenovirus e serotype 4 strain cl-68578 antigen is combined with Oxaliplatin. Hydrochlorothiazide The risk or severity of QTc prolongation can be increased when Hydrochlorothiazide is combined with Oxaliplatin. Hydrocortisone The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Hydrocortisone acetate. Hydrocortisone The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Hydrocortisone butyrate. Hydrocortisone The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Hydrocortisone succinate. Hydroflumethiazide The risk or severity of neutropenia and thrombocytopenia can be increased when Hydroflumethiazide is combined with Oxaliplatin. Hydroxychloroquine The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Hydroxychloroquine. Hydroxyurea The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Hydroxyurea. Hydroxyzine The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Hydroxyzine. Hyoscyamine The risk or severity of QTc prolongation can be increased when Hyoscyamine is combined with Oxaliplatin. Ibandronate The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Oxaliplatin. Ibritumomab tiuxetan The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Oxaliplatin. Ibrutinib The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Ibrutinib. Ibutilide The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Ibutilide. Icosapent ethyl The risk or severity of bleeding can be increased when Icosapent ethyl is combined with Oxaliplatin. Idarubicin The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Idarubicin. Idelalisib The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Idelalisib. Ifosfamide The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Ifosfamide. Iloperidone The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Iloperidone. Iloprost The risk or severity of bleeding can be increased when Iloprost is combined with Oxaliplatin. Imatinib The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Imatinib. Imipramine The serum concentration of Oxaliplatin can be increased when it is combined with Imipramine. Indacaterol The risk or severity of QTc prolongation can be increased when Indacaterol is combined with Oxaliplatin. Indapamide The risk or severity of QTc prolongation can be increased when Indapamide is combined with Oxaliplatin. Indomethacin The risk or severity of adverse effects can be increased when Indomethacin is combined with Oxaliplatin. Inebilizumab The risk or severity of infection can be increased when Oxaliplatin is combined with Inebilizumab. Infliximab The risk or severity of adverse effects can be increased when Infliximab is combined with Oxaliplatin. Influenza A virus A The therapeutic efficacy of Influenza A virus A/Brisbane/59/2007(H1N1) antigen (propiolactone inactivated) can be decreased when used in combination with Oxaliplatin. Influenza A virus A The therapeutic efficacy of Influenza A virus A/Brisbane/59/2007(H1N1) hemagglutinin antigen (propiolactone inactivated) can be decreased when used in combination with Oxaliplatin. Influenza A virus A The therapeutic efficacy of Influenza A virus A/California/7/2009 (H1N1) live (attenuated) antigen can be decreased when used in combination with Oxaliplatin. Influenza A virus The therapeutic efficacy of Influenza A virus A/California/7/2009 X-181 (H1N1) antigen (propiolactone inactivated) can be decreased when used in combination with Oxaliplatin. Influenza A virus A The therapeutic efficacy of Influenza A virus A/California/7/2009 X-181 (H1N1) hemagglutinin antigen (propiolactone inactivated) can be decreased when used in combination with Oxaliplatin. Influenza A virus The therapeutic efficacy of Influenza A virus A/Perth/16/2009 (H3N2) live (attenuated) antigen can be decreased when used in combination with Oxaliplatin. Influenza A virus The therapeutic efficacy of Influenza A virus A/Uruguay/716/2007(H3N2) antigen (propiolactone inactivated) can be decreased when used in combination with Oxaliplatin. Influenza A virus A The therapeutic efficacy of Influenza A virus A/Victoria/210/2009 X-187 (H3N2) antigen (formaldehyde inactivated) can be decreased when used in combination with Oxaliplatin. Influenza A virus A The therapeutic efficacy of Influenza A virus A/Victoria/210/2009 X-187 (H3N2) hemagglutinin antigen (formaldehyde inactivated) can be decreased when used in combination with Oxaliplatin. Influenza B virus B The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 antigen (formaldehyde inactivated) can be decreased when used in combination with Oxaliplatin. Influenza B virus B The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 antigen (propiolactone inactivated) can be decreased when used in combination with Oxaliplatin. Influenza B virus B The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (formaldehyde inactivated) can be decreased when used in combination with Oxaliplatin. Influenza B virus The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (propiolactone inactivated) can be decreased when used in combination with Oxaliplatin. Inotersen The risk or severity of QTc prolongation can be increased when Inotersen is combined with Oxaliplatin. Interferon alfa-2a The risk or severity of adverse effects can be increased when Interferon alfa-2a is combined with Oxaliplatin. Interferon alfa-2b The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Oxaliplatin. Interferon alfa-n1 The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Oxaliplatin. Interferon alfa-n3 The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Oxaliplatin. Interferon alfacon-1 The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Oxaliplatin. Interferon beta-1b The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Oxaliplatin. Interferon gamma-1b The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Oxaliplatin. Irinotecan The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Irinotecan. Isavuconazole The serum concentration of Oxaliplatin can be increased when it is combined with Isavuconazole. Isoflurane The risk or severity of QTc prolongation can be increased when Isoflurane is combined with Oxaliplatin. Istradefylline Istradefylline may decrease the excretion rate of Oxaliplatin which could result in a higher serum level. Itraconazole Itraconazole may decrease the excretion rate of Oxaliplatin which could result in a higher serum level. Ivabradine Ivabradine may increase the QTc-prolonging activities of Oxaliplatin. Ivosidenib The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Ivosidenib. Ixabepilone The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Ixabepilone. Ixekizumab The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Ixekizumab. Janssen COVID-19 The therapeutic efficacy of Janssen COVID-19 Vaccine can be decreased when used in combination with Oxaliplatin. Japanese encephalitis The therapeutic efficacy of Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated) can be decreased when used in combination with Oxaliplatin. Ketoconazole The risk or severity of QTc prolongation can be increased when Ketoconazole is combined with Oxaliplatin. Lacidipine The risk or severity of QTc prolongation can be increased when Lacidipine is combined with Oxaliplatin. Lamotrigine The serum concentration of Oxaliplatin can be increased when it is combined with Lamotrigine. Lansoprazole Lansoprazole may decrease the excretion rate of Oxaliplatin which could result in a higher serum level. Lapatinib The risk or severity of QTc prolongation can be increased when Lapatinib is combined with Oxaliplatin. Lasmiditan The serum concentration of Oxaliplatin can be increased when it is combined with Lasmiditan. Ledipasvir Ledipasvir may decrease the excretion rate of Oxaliplatin which could result in a higher serum level. Lefamulin Lefamulin may increase the QTc-prolonging activities of Oxaliplatin. Leflunomide The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Leflunomide. Lenalidomide The risk or severity of adverse effects can be increased when Lenalidomide is combined with Oxaliplatin. Lenvatinib The serum concentration of Oxaliplatin can be increased when it is combined with Lenvatinib. Lepirudin The risk or severity of bleeding can be increased when Lepirudin is combined with Oxaliplatin. Letermovir Letermovir may decrease the excretion rate of Oxaliplatin which could result in a higher serum level. Leuprolide The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Oxaliplatin. Levacetylmethadol The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Levacetylmethadol. Levobupivacaine The risk or severity of methemoglobinemia can be increased when Oxaliplatin is combined with Levobupivacaine. Levocabastine The risk or severity of QTc prolongation can be increased when Levocabastine is combined with Oxaliplatin. Levocetirizine The risk or severity of QTc prolongation can be increased when Levocetirizine is combined with Oxaliplatin. Levofloxacin The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Levofloxacin. Levoketoconazole The serum concentration of Oxaliplatin can be increased when it is combined with Levoketoconazole. Levomenthol The risk or severity of QTc prolongation can be increased when Levomenthol is combined with Oxaliplatin. Levosimendan The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Levosimendan. Lidocaine The risk or severity of methemoglobinemia can be increased when Oxaliplatin is combined with Lidocaine. Lidoflazine The risk or severity of QTc prolongation can be increased when Lidoflazine is combined with Oxaliplatin. Linagliptin The serum concentration of Oxaliplatin can be increased when it is combined with Linagliptin. Linezolid The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Linezolid. Lipegfilgrastim Oxaliplatin may increase the myelosuppressive activities of Lipegfilgrastim. Lofexidine The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Lofexidine. Lomefloxacin The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Lomefloxacin. Lomustine The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Lomustine. Loperamide The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Loperamide. Lopinavir The serum concentration of Oxaliplatin can be increased when it is combined with Lopinavir. Losartan The risk or severity of QTc prolongation can be increased when Losartan is combined with Oxaliplatin. Lumefantrine The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Lumefantrine. Lurasidone The risk or severity of QTc prolongation can be increased when Lurasidone is combined with Oxaliplatin. Macimorelin The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Macimorelin. Magnesium The serum concentration of Magnesium can be decreased when it is combined with Oxaliplatin. Maprotiline The risk or severity of QTc prolongation can be increased when Maprotiline is combined with Oxaliplatin. Maribavir Maribavir may decrease the excretion rate of Oxaliplatin which could result in a higher serum level. Measles virus The therapeutic efficacy of Measles virus vaccine live attenuated can be decreased when used in combination with Oxaliplatin. Mechlorethamine The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Mechlorethamine. Mefloquine The risk or severity of QTc prolongation can be increased when Mefloquine is combined with Oxaliplatin. Meloxicam The risk or severity of methemoglobinemia can be increased when Oxaliplatin is combined with Meloxicam. Melphalan The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Melphalan. Meningococcal The therapeutic efficacy of Meningococcal (groups A, C, Y and W-135) oligosaccharide diphtheria CRM197 conjugate vaccine can be decreased when used in combination with Oxaliplatin. Mepivacaine The risk or severity of methemoglobinemia can be increased when Oxaliplatin is combined with Mepivacaine. Mepolizumab The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Mepolizumab. Meprednisone The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Meprednisone. Mepyramine The risk or severity of QTc prolongation can be increased when Mepyramine is combined with Oxaliplatin. Mercaptopurine The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Mercaptopurine. Mesoridazine The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Mesoridazine. Methadone The risk or severity of QTc prolongation can be increased when Methadone is combined with Oxaliplatin. Methimazole The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Methimazole. Methotrexate The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Methotrexate. Methotrimeprazine The risk or severity of QTc prolongation can be increased when Methotrimeprazine is combined with Oxaliplatin. Methoxy The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Oxaliplatin. Methsuximide The risk or severity of QTc prolongation can be increased when Methsuximide is combined with Oxaliplatin. Methylene blue The serum concentration of Oxaliplatin can be increased when it is combined with Methylene blue. Methylprednisolone The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Methylprednisolone. Metoclopramide The risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Oxaliplatin. Metoprolol The serum concentration of Oxaliplatin can be increased when it is combined with Metoprolol. Metronidazole The risk or severity of QTc prolongation can be increased when Metronidazole is combined with Oxaliplatin. Mifepristone The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Mifepristone. Mirabegron The risk or severity of QTc prolongation can be increased when Mirabegron is combined with Oxaliplatin. Mirtazapine The risk or severity of QTc prolongation can be increased when Mirtazapine is combined with Oxaliplatin. Mitomycin The risk or severity of adverse effects can be increased when Mitomycin is combined with Oxaliplatin. Mitoxantrone The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Mitoxantrone. Mizolastine The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Mizolastine. Mobocertinib The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Mobocertinib. COVID-19 Vaccine The therapeutic efficacy of Moderna COVID-19 Vaccine can be decreased when used in combination with Oxaliplatin. Modified vaccinia ankara The therapeutic efficacy of Modified vaccinia ankara can be decreased when used in combination with Oxaliplatin. Moexipril The risk or severity of QTc prolongation can be increased when Moexipril is combined with Oxaliplatin. Mometasone furoate The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Mometasone furoate. Monomethyl fumarate The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Monomethyl fumarate. Moricizine The risk or severity of QTc prolongation can be increased when Moricizine is combined with Oxaliplatin. Mosunetuzumab The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Mosunetuzumab. Moxifloxacin The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Oxaliplatin. Mumps virus The therapeutic efficacy of Mumps virus strain B level jeryl lynn live antigen can be decreased when used in combination with Oxaliplatin. Muromonab The risk or severity of adverse effects can be increased when Muromonab is combined with Oxaliplatin. Mycophenolate mofetil The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Mycophenolate mofetil. Mycophenolic acid The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Mycophenolic acid. Nadroparin The risk or severity of bleeding can be increased when Nadroparin is combined with Oxaliplatin. Nalidixic acid The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Nalidixic acid. Natalizumab The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Natalizumab. Nelarabine The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Nelarabine. Nelfinavir Nelfinavir may decrease the excretion rate of Oxaliplatin which could result in a higher serum level. Nicardipine The risk or severity of QTc prolongation can be increased when Nicardipine is combined with Oxaliplatin. Nicotine The serum concentration of Oxaliplatin can be increased when it is combined with Nicotine. Nifedipine The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Nifedipine. Nilotinib The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Nilotinib. Nilvadipine The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Nilvadipine. Nimodipine The risk or severity of QTc prolongation can be increased when Nimodipine is combined with Oxaliplatin. Nitrendipine The risk or severity of QTc prolongation can be increased when Nitrendipine is combined with Oxaliplatin. Norepinephrine The serum concentration of Oxaliplatin can be increased when it is combined with Norepinephrine. Norfloxacin The risk or severity of QTc prolongation can be increased when Norfloxacin is combined with Oxaliplatin. Nortriptyline The risk or severity of QTc prolongation can be increased when Nortriptyline is combined with Oxaliplatin. Novobiocin Novobiocin may decrease the excretion rate of Oxaliplatin which could result in a higher serum level. Nuvaxovid The therapeutic efficacy of Nuvaxovid can be decreased when used in combination with Oxaliplatin. Obinutuzumab The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Obinutuzumab. Ocrelizumab Ocrelizumab may increase the immunosuppressive activities of Oxaliplatin. Octreotide The risk or severity of QTc prolongation can be increased when Octreotide is combined with Oxaliplatin. Ofatumumab The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Ofatumumab. Ofloxacin The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Ofloxacin. Olanzapine The risk or severity of QTc prolongation can be increased when Olanzapine is combined with Oxaliplatin. Olaparib The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Olaparib. Olodaterol The risk or severity of QTc prolongation can be increased when Olodaterol is combined with Oxaliplatin. Omeprazole Omeprazole may decrease the excretion rate of Oxaliplatin which could result in a higher serum level. Ondansetron The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Ondansetron. Orphenadrine The risk or severity of QTc prolongation can be increased when Orphenadrine is combined with Oxaliplatin. Osimertinib Osimertinib may decrease the excretion rate of Oxaliplatin which could result in a higher serum level. Oteseconazole The serum concentration of Oxaliplatin can be increased when it is combined with Oteseconazole. Oxatomide The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Oxatomide. Oxetacaine The risk or severity of methemoglobinemia can be increased when Oxaliplatin is combined with Oxetacaine. Oxprenolol The serum concentration of Oxaliplatin can be increased when it is combined with Oxprenolol. Oxybuprocaine The risk or severity of methemoglobinemia can be increased when Oxaliplatin is combined with Oxybuprocaine. Oxytocin The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Oxaliplatin. Ozanimod The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Ozanimod. Paclitaxel The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Paclitaxel. Pacritinib The serum concentration of Oxaliplatin can be increased when it is combined with Pacritinib. Palbociclib The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Palbociclib. Palifermin The therapeutic efficacy of Palifermin can be decreased when used in combination with Oxaliplatin. Paliperidone The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Paliperidone. Panobinostat The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Panobinostat. Pantoprazole Pantoprazole may decrease the excretion rate of Oxaliplatin which could result in a higher serum level. Papaverine The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Papaverine. Paritaprevir Paritaprevir may decrease the excretion rate of Oxaliplatin which could result in a higher serum level. Parnaparin The risk or severity of bleeding can be increased when Parnaparin is combined with Oxaliplatin. Pasireotide The risk or severity of QTc prolongation can be increased when Pasireotide is combined with Oxaliplatin. Pazopanib The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Pazopanib. Pefloxacin The risk or severity of QTc prolongation can be increased when Pefloxacin is combined with Oxaliplatin. Pegaspargase The risk or severity of adverse effects can be increased when Pegaspargase is combined with Oxaliplatin. Pegcetacoplan The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Pegcetacoplan. Peginesatide The risk or severity of Thrombosis can be increased when Peginesatide is combined with Oxaliplatin. Peginterferon alfa The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Oxaliplatin. Peginterferon alf The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Oxaliplatin. Peginterferon beta The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Peginterferon beta-1a. Pemetrexed The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Pemetrexed. Penicillamine The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Penicillamine. Pentamidine The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Pentamidine. Pentosan polysulfate The risk or severity of bleeding can be increased when Pentosan polysulfate is combined with Oxaliplatin. Pentostatin The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Pentostatin. Pentoxifylline The risk or severity of bleeding can be increased when Pentoxifylline is combined with Oxaliplatin. Perflutren The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Perflutren. Perhexiline The risk or severity of QTc prolongation can be increased when Perhexiline is combined with Oxaliplatin. Pertussis vaccine The therapeutic efficacy of Pertussis vaccine can be decreased when used in combination with Oxaliplatin. Phenformin The serum concentration of Oxaliplatin can be increased when it is combined with Phenformin. Phenindione The risk or severity of bleeding can be increased when Phenindione is combined with Oxaliplatin. Pheniramine The risk or severity of QTc prolongation can be increased when Pheniramine is combined with Oxaliplatin. Phenol The risk or severity of methemoglobinemia can be increased when Oxaliplatin is combined with Phenol. Phenoxybenzamine The serum concentration of Oxaliplatin can be increased when it is combined with Phenoxybenzamine. Phenprocoumon The risk or severity of bleeding can be increased when Phenprocoumon is combined with Oxaliplatin. Phenylalanine The risk or severity of adverse effects can be increased when Phenylalanine is combined with Oxaliplatin. Phenytoin Oxaliplatin can cause a decrease in the absorption of Phenytoin resulting in a reduced serum concentration and potentially a decrease in efficacy. Pibrentasvir Pibrentasvir may decrease the excretion rate of Oxaliplatin which could result in a higher serum level. Pimecrolimus The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Oxaliplatin. Pimozide The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Pimozide. Pinaverium The risk or severity of QTc prolongation can be increased when Pinaverium is combined with Oxaliplatin. Pirfenidone The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Pirfenidone. Pitolisant Oxaliplatin may increase the QTc-prolonging activities of Pitolisant. Polythiazide The risk or severity of neutropenia and thrombocytopenia can be increased when Polythiazide is combined with Oxaliplatin. Pomalidomide The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Pomalidomide. Ponatinib The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Ponatinib. Ponesimod The risk or severity of bradycardia can be increased when Ponesimod is combined with Oxaliplatin. Posaconazole The risk or severity of QTc prolongation can be increased when Posaconazole is combined with Oxaliplatin. Pralatrexate The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Pralatrexate. Pralsetinib Pralsetinib may decrease the excretion rate of Oxaliplatin which could result in a higher serum level. Pramocaine The risk or severity of methemoglobinemia can be increased when Oxaliplatin is combined with Pramocaine. Prasugrel The risk or severity of bleeding can be increased when Prasugrel is combined with Oxaliplatin. Pravastatin Pravastatin may decrease the excretion rate of Oxaliplatin which could result in a higher serum level. Prednisolone The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Prednisolone. Prednisone The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Prednisone. Pregabalin The risk or severity of QTc prolongation can be increased when Pregabalin is combined with Oxaliplatin. Prenylamine The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Prenylamine. Prilocaine The risk or severity of methemoglobinemia can be increased when Oxaliplatin is combined with Prilocaine. Primaquine The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Primaquine. Probenecid The serum concentration of Oxaliplatin can be increased when it is combined with Probenecid. Probucol The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Probucol. Procainamide The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Procainamide. Procaine The risk or severity of methemoglobinemia can be increased when Oxaliplatin is combined with Procaine. Procarbazine The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Procarbazine. Prochlorperazine The risk or severity of QTc prolongation can be increased when Prochlorperazine is combined with Oxaliplatin. Progesterone The serum concentration of Oxaliplatin can be increased when it is combined with Progesterone. Promazine The risk or severity of QTc prolongation can be increased when Promazine is combined with Oxaliplatin. Promethazine The risk or severity of QTc prolongation can be increased when Promethazine is combined with Oxaliplatin. Propafenone The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Propafenone. Proparacaine The risk or severity of methemoglobinemia can be increased when Oxaliplatin is combined with Proparacaine. Propofol The risk or severity of QTc prolongation can be increased when Propofol is combined with Oxaliplatin. Propoxycaine The risk or severity of methemoglobinemia can be increased when Oxaliplatin is combined with Propoxycaine. Propranolol The serum concentration of Oxaliplatin can be increased when it is combined with Propranolol. Propylthiouracil The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Propylthiouracil. Protein C The risk or severity of bleeding can be increased when Protein C is combined with Oxaliplatin. Protein S human The risk or severity of bleeding can be increased when Protein S human is combined with Oxaliplatin. Protriptyline The risk or severity of QTc prolongation can be increased when Protriptyline is combined with Oxaliplatin. Quetiapine The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Quetiapine. Quinidine The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Quinidine. Quinine The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Quinine. Rabeprazole Rabeprazole may decrease the excretion rate of Oxaliplatin which could result in a higher serum level. Rabies immune The therapeutic efficacy of Rabies immune globulin, human can be decreased when used in combination with Oxaliplatin. Rabies virus inactivated The therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Oxaliplatin. Rabies virus inactivated The therapeutic efficacy of Rabies virus inactivated antigen, B can be decreased when used in combination with Oxaliplatin. Raltitrexed The risk or severity of adverse effects can be increased when Raltitrexed is combined with Oxaliplatin. Ranitidine The serum concentration of Oxaliplatin can be increased when it is combined with Ranitidine. Ranolazine The serum concentration of Oxaliplatin can be increased when it is combined with Ranolazine. Ravulizumab The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Ravulizumab. Regorafenib Regorafenib may decrease the excretion rate of Oxaliplatin which could result in a higher serum level. Relugolix The risk or severity of QTc prolongation can be increased when Relugolix is combined with Oxaliplatin. Reteplase The risk or severity of bleeding can be increased when Reteplase is combined with Oxaliplatin. Reviparin The risk or severity of bleeding can be increased when Reviparin is combined with Oxaliplatin. Ribociclib The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Ribociclib. Rilonacept The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Rilonacept. Rilpivirine Rilpivirine may decrease the excretion rate of Oxaliplatin which could result in a higher serum level. Ripretinib Ripretinib may decrease the excretion rate of Oxaliplatin which could result in a higher serum level. Risankizumab The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Risankizumab. Risperidone The risk or severity of QTc prolongation can be increased when Risperidone is combined with Oxaliplatin. Ritonavir Ritonavir may decrease the excretion rate of Oxaliplatin which could result in a higher serum level. Rituximab The risk or severity of adverse effects can be increased when Rituximab is combined with Oxaliplatin. Rivaroxaban The risk or severity of bleeding can be increased when Rivaroxaban is combined with Oxaliplatin. Roflumilast Roflumilast may increase the immunosuppressive activities of Oxaliplatin. Rolapitant Rolapitant may decrease the excretion rate of Oxaliplatin which could result in a higher serum level. Romidepsin The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Romidepsin. Ropeginterferon alfa The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Ropeginterferon alfa-2b. Ropivacaine The risk or severity of methemoglobinemia can be increased when Oxaliplatin is combined with Ropivacaine. Rosoxacin The risk or severity of QTc prolongation can be increased when Rosoxacin is combined with Oxaliplatin. Rotavirus vaccine The therapeutic efficacy of Rotavirus vaccine can be decreased when used in combination with Oxaliplatin. Roxadustat The serum concentration of Oxaliplatin can be increased when it is combined with Roxadustat. Roxithromycin The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Roxithromycin. Rubella virus vaccine The risk or severity of infection can be increased when Rubella virus vaccine is combined with Oxaliplatin. Rucaparib Rucaparib may decrease the excretion rate of Oxaliplatin which could result in a higher serum level. Rupatadine The risk or severity of QTc prolongation can be increased when Rupatadine is combined with Oxaliplatin. Ruxolitinib The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Ruxolitinib. Safinamide Safinamide may decrease the excretion rate of Oxaliplatin which could result in a higher serum level. Salbutamol The risk or severity of QTc prolongation can be increased when Salbutamol is combined with Oxaliplatin. Salmeterol The serum concentration of Oxaliplatin can be increased when it is combined with Salmeterol. Saquinavir The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Saquinavir. Sarilumab The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Sarilumab. Satralizumab The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Satralizumab. Secukinumab The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Secukinumab. Sevoflurane The risk or severity of QTc prolongation can be increased when Sevoflurane is combined with Oxaliplatin. Siltuximab The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Siltuximab. Simeprevir Simeprevir may decrease the excretion rate of Oxaliplatin which could result in a higher serum level. Siponimod The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Siponimod. Sipuleucel-T The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Oxaliplatin. Sirolimus The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Sirolimus. Smallpox The therapeutic efficacy of Smallpox (Vaccinia) Vaccine, Live can be decreased when used in combination with Oxaliplatin. Sodium citrate The risk or severity of bleeding can be increased when Sodium citrate is combined with Oxaliplatin. Solifenacin The risk or severity of QTc prolongation can be increased when Solifenacin is combined with Oxaliplatin. Sorafenib The risk or severity of adverse effects can be increased when Sorafenib is combined with Oxaliplatin. Sotagliflozin Sotagliflozin may decrease the excretion rate of Oxaliplatin which could result in a higher serum level. Sotalol The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Sotalol. Sparfloxacin The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Sparfloxacin. Spesolimab The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Spesolimab. Stiripentol The excretion of Oxaliplatin can be decreased when combined with Stiripentol. Streptokinase The risk or severity of bleeding can be increased when Streptokinase is combined with Oxaliplatin. Streptozocin The risk or severity of adverse effects can be increased when Streptozocin is combined with Oxaliplatin. Sulfamethoxazole The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Oxaliplatin. Sulfasalazine The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Sulfasalazine. Sulfinpyrazone The risk or severity of bleeding can be increased when Sulfinpyrazone is combined with Oxaliplatin. Sulfisoxazole The risk or severity of QTc prolongation can be increased when Sulfisoxazole is combined with Oxaliplatin. Sulodexide The risk or severity of bleeding can be increased when Sulodexide is combined with Oxaliplatin. Sulpiride The risk or severity of QTc prolongation can be increased when Sulpiride is combined with Oxaliplatin. Sultopride The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Sultopride. Sunitinib The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Sunitinib. Tacrolimus Tacrolimus may increase the immunosuppressive activities of Oxaliplatin. Tafamidis The serum concentration of Oxaliplatin can be increased when it is combined with Tafamidis. Tafenoquine The serum concentration of Oxaliplatin can be increased when it is combined with Tafenoquine. Tamoxifen The risk or severity of QTc prolongation can be increased when Tamoxifen is combined with Oxaliplatin. Taurocholic acid Taurocholic acid may decrease the excretion rate of Oxaliplatin which could result in a higher serum level. Tedizolid phosphate The risk or severity of myelosuppression can be increased when Oxaliplatin is combined with Tedizolid phosphate. Telavancin The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Telavancin. Telithromycin The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Telithromycin. Telmisartan Telmisartan may decrease the excretion rate of Oxaliplatin which could result in a higher serum level. Temozolomide The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Temozolomide. Temsirolimus The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Temsirolimus. Tenecteplase The risk or severity of bleeding can be increased when Tenecteplase is combined with Oxaliplatin. Teniposide The risk or severity of adverse effects can be increased when Teniposide is combined with Oxaliplatin. Tepotinib Tepotinib may decrease the excretion rate of Oxaliplatin which could result in a higher serum level. Teprotumumab The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Teprotumumab. Terbutaline The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Oxaliplatin. Terfenadine The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Terfenadine. Teriflunomide The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Teriflunomide. Terlipressin The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Terlipressin. Tetrabenazine The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Tetrabenazine. Tetracaine The risk or severity of methemoglobinemia can be increased when Oxaliplatin is combined with Tetracaine. Thalidomide The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Thalidomide. Thiamine The serum concentration of Oxaliplatin can be increased when it is combined with Thiamine. Thioridazine The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Thioridazine. Thiotepa The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Thiotepa. Thiothixene The risk or severity of QTc prolongation can be increased when Thiothixene is combined with Oxaliplatin. Ticagrelor The risk or severity of bleeding can be increased when Ticagrelor is combined with Oxaliplatin. Timolol The risk or severity of QTc prolongation can be increased when Timolol is combined with Oxaliplatin. Tinzaparin The risk or severity of bleeding can be increased when Tinzaparin is combined with Oxaliplatin. Tioguanine The risk or severity of adverse effects can be increased when Tioguanine is combined with Oxaliplatin. Tirofiban The risk or severity of bleeding can be increased when Tirofiban is combined with Oxaliplatin. Tivozanib Tivozanib may decrease the excretion rate of Oxaliplatin which could result in a higher serum level. Tixocortol The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Tixocortol. Tizanidine The risk or severity of QTc prolongation can be increased when Tizanidine is combined with Oxaliplatin. Tocilizumab The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Tocilizumab. Tofacitinib Oxaliplatin may increase the immunosuppressive activities of Tofacitinib. Tolterodine The risk or severity of QTc prolongation can be increased when Tolterodine is combined with Oxaliplatin. Topotecan The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Topotecan. Toremifene The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Toremifene. Tositumomab The risk or severity of adverse effects can be increased when Tositumomab is combined with Oxaliplatin. Trabectedin The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Trabectedin. Trastuzumab Trastuzumab may increase the neutropenic activities of Oxaliplatin. Trastuzumab The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Trastuzumab emtansine. Trazodone The risk or severity of QTc prolongation can be increased when Trazodone is combined with Oxaliplatin. Treprostinil The risk or severity of QTc prolongation can be increased when Treprostinil is combined with Oxaliplatin. Tretinoin The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Tretinoin. Triamcinolone The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Triamcinolone. Trichlormethiazide The risk or severity of neutropenia and thrombocytopenia can be increased when Trichlormethiazide is combined with Oxaliplatin. Triclabendazole The risk or severity of QTc prolongation can be increased when Triclabendazole is combined with Oxaliplatin. Trifluridine The risk or severity of adverse effects can be increased when Trifluridine is combined with Oxaliplatin. Triflusal The risk or severity of bleeding can be increased when Triflusal is combined with Oxaliplatin. Trilaciclib The serum concentration of Oxaliplatin can be increased when it is combined with Trilaciclib. Trilostane The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Trilostane. Trimebutine The risk or severity of QTc prolongation can be increased when Trimebutine is combined with Oxaliplatin. Trimethadione The risk or severity of QTc prolongation can be increased when Trimethadione is combined with Oxaliplatin. Trimethoprim The serum concentration of Oxaliplatin can be increased when it is combined with Trimethoprim. Trimipramine The risk or severity of QTc prolongation can be increased when Trimipramine is combined with Oxaliplatin. Triprolidine The risk or severity of QTc prolongation can be increased when Triprolidine is combined with Oxaliplatin. Triptorelin The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Oxaliplatin. Trovafloxacin The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Trovafloxacin. Tucatinib The serum concentration of Oxaliplatin can be increased when it is combined with Tucatinib. Typhoid vaccine The therapeutic efficacy of Typhoid vaccine can be decreased when used in combination with Oxaliplatin. Typhoid Vaccine Live The risk or severity of infection can be increased when Typhoid Vaccine Live is combined with Oxaliplatin. Typhoid The therapeutic efficacy of Typhoid Vi polysaccharide vaccine can be decreased when used in combination with Oxaliplatin. Upadacitinib The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Upadacitinib. Urokinase The risk or severity of bleeding can be increased when Urokinase is combined with Oxaliplatin. Valproic acid The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Valproic acid. Vandetanib The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Vandetanib. Vardenafil The risk or severity of QTc prolongation can be increased when Vardenafil is combined with Oxaliplatin. Varenicline The serum concentration of Oxaliplatin can be increased when it is combined with Varenicline. Varicella zoster The risk or severity of infection can be increased when Varicella zoster vaccine (live/attenuated) is combined with Oxaliplatin. Varicella zoster The therapeutic efficacy of Varicella zoster vaccine (recombinant) can be decreased when used in combination with Oxaliplatin. Vedolizumab The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Vedolizumab. Velpatasvir Velpatasvir may decrease the excretion rate of Oxaliplatin which could result in a higher serum level. Vemurafenib The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Vemurafenib. Venetoclax Venetoclax may decrease the excretion rate of Oxaliplatin which could result in a higher serum level. Venlafaxine Venlafaxine may increase the excretion rate of Oxaliplatin which could result in a lower serum level and potentially a reduction in efficacy. Vernakalant The risk or severity of QTc prolongation can be increased when Vernakalant is combined with Oxaliplatin. Vibrio cholerae The therapeutic efficacy of Vibrio cholerae CVD 103-HgR strain live antigen can be decreased when used in combination with Oxaliplatin. Vilanterol The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Vilanterol. Vinblastine The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Vinblastine. Vincristine The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Vincristine. Vindesine The risk or severity of adverse effects can be increased when Vindesine is combined with Oxaliplatin. Vinorelbine The risk or severity of adverse effects can be increased when Vinorelbine is combined with Oxaliplatin. Vismodegib Vismodegib may decrease the excretion rate of Oxaliplatin which could result in a higher serum level. Voclosporin The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Voclosporin. Vorapaxar The risk or severity of bleeding can be increased when Vorapaxar is combined with Oxaliplatin. Voriconazole The risk or severity of QTc prolongation can be increased when Voriconazole is combined with Oxaliplatin. Vorinostat The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Vorinostat. Voxilaprevir Voxilaprevir may decrease the excretion rate of Oxaliplatin which could result in a higher serum level. Warfarin The risk or severity of bleeding can be increased when Warfarin is combined with Oxaliplatin. Ximelagatran The risk or severity of bleeding can be increased when Ximelagatran is combined with Oxaliplatin. Yellow fever vaccine The risk or severity of infection can be increased when Yellow fever vaccine is combined with Oxaliplatin. Zidovudine The risk or severity of adverse effects can be increased when Zidovudine is combined with Oxaliplatin. Ziprasidone The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Ziprasidone. Zonisamide The risk or severity of QTc prolongation can be increased when Zonisamide is combined with Oxaliplatin. Zuclopenthixol The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Zuclopenthixol. Pregnancy and Lactation US FDA pregnancy category D Pregnancy If you are pregnant or plan to become pregnant. Oxaliplatin may harm your unborn baby. Tell your doctor right away if you become pregnant or think you may be pregnant during treatment with oxaliplatin. You are able to become pregnant, your doctor may do a pregnancy test before you start treatment with oxaliplatin and for 9 months after the final dose. Talk to your doctor about forms of birth control that may be right for you. Lactation If you are breastfeeding or plan to breastfeed. It is not known if oxaliplatin passes into your breast milk. Do not breastfeed during treatment with oxaliplatin and for 3 months after the final dose. Females who are able to become pregnant should avoid becoming pregnant and should use effective birth control during treatment with oxaliplatin and for 9 months after the final dose. Talk to your doctor about forms of birth control that may be right for you. Males with female partners who are pregnant or able to become pregnant should use effective birth control during treatment with oxaliplatin and for 6 months after the final dose. Oxaliplatin may cause fertility problems in males and females. Talk to your doctor if this is a concern for you. What special precautions should I follow? Before using oxaliplatin, tell your doctor and pharmacist what prescription and nonprescription medications, vitamins, nutritional supplements, and herbal products you are taking or plan to take. Be sure to mention oral anticoagulants (‘blood thinners) such as warfarin (Coumadin). Your doctor may need to change the doses of your medications or monitor you carefully for side effects. tell your doctor if you have or have ever had kidney disease. tell your doctor if you are pregnant or plan to become pregnant. Oxaliplatin may harm the fetus. You should use birth control to prevent pregnancy during your treatment with oxaliplatin. Talk to your doctor about the types of birth control that will work for you.If you become pregnant while taking oxaliplatin, call your doctor. Do not breastfeed during your treatment with oxaliplatin. if you are having surgery, including dental surgery, tell the doctor or dentist that you are using oxaliplatin. you should know that oxaliplatin may decrease your ability to fight infection. Stay away from people who are sick during your treatment with oxaliplatin. you should know that exposure to cold air or objects may make some of the side effects of oxaliplatin worse. You should not eat or drink anything colder than room temperature, touch any cold objects, go near air conditioners or freezers, wash your hands in cold water, or go outside in cold weather unless absolutely necessary for five days after you receive each dose of oxaliplatin. If you must go outside in cold weather, wear a hat, gloves, and a scarf, and cover your mouth and nose. References https://www.cancer.gov/about-cancer/treatment/drugs/capox https://go.drugbank.com/drugs/DB00526 https://en.wikipedia.org/wiki/Oxaliplatin https://www.drugs.com/oxaliplatin.html https://medlineplus.gov/druginfo/meds/a607035.html https://pubchem.ncbi.nlm.nih.gov/compound/Oxaliplatin https://pubchem.ncbi.nlm.nih.gov/compound/Oxaliplatine https://www.webmd.com/drugs/2/drug-64025/oxaliplatin-intravenous/details/list-contraindications https://www.ncbi.nlm.nih.gov/books/ ChemIDplus LICENSE https://www.nlm.nih.gov/copyright.html Oxaliplatin [USAN:USP:INN:BAN] https://chem.nlm.nih.gov/chemidplus/sid/0061825943 DrugBank https://www.drugbank.ca/legal/terms_of_use Oxaliplatin https://www.drugbank.ca/drugs/DB00526 EPA DSSTox LICENSE https://www.epa.gov/privacy/privacy-act-laws-policies-and-resources Oxaliplatin https://comptox.epa.gov/dashboard/DTXSID0036760 CompTox Chemicals Dashboard Chemical Lists https://comptox.epa.gov/dashboard/chemical-lists/ European Chemicals Agency (ECHA) https://echa.europa.eu/web/guest/legal-notice Oxaliplatin https://echa.europa.eu/information-on-chemicals Oxaliplatin https://echa.europa.eu/information-on-chemicals/cl-inventory-database/-/discli/details/154685 ClinicalTrials.gov https://clinicaltrials.gov/ct2/about-site/terms-conditions#Use https://clinicaltrials.gov/ DailyMed LICENSE https://www.nlm.nih.gov/copyright.html OXALIPLATIN https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=OXALIPLATIN LiverTox LICENSE https://www.nlm.nih.gov/copyright.html Oxaliplatin https://www.ncbi.nlm.nih.gov/books/n/livertox/Oxaliplatin/ NCI Thesaurus (NCIt) https://www.cancer.gov/policies/copyright-reuse https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C1181 Nature Chemical Biology https://pubchem.ncbi.nlm.nih.gov/substance/46095912 Therapeutic Target Database (TTD) Oxaliplatin http://idrblab.net/ttd/data/drug/details/D0Y3ME EU Clinical Trials Register https://www.clinicaltrialsregister.eu/ FDA Orange Book https://www.fda.gov/about-fda/about-website/website-policies#linking https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book National Drug Code (NDC) Directory LICENSE https://www.fda.gov/about-fda/about-website/website-policies#linking OXALIPLATIN https://www.fda.gov/drugs/drug-approvals-and-databases/national-drug-code-directory NCI Cancer Drugs LICENSE https://www.cancer.gov/policies/copyright-reuse Eloxatin (Oxaliplatin) https://www.cancer.gov/about-cancer/treatment/drugs/oxaliplatin NIPH Clinical Trials Search of Japan https://rctportal.niph.go.jp/en/ NLM RxNorm Terminology https://www.nlm.nih.gov/research/umls/rxnorm/docs/termsofservice.html oxaliplatin https://rxnav.nlm.nih.gov/id/rxnorm/32592 NORMAN Suspect List Exchange LICENSE Data: CC-BY 4.0; Code (hosted by ECI, LCSB): Artistic-2.0 https://creativecommons.org/licenses/by/4.0/ NORMAN Suspect List Exchange Classification https://www.norman-network.com/nds/SLE/ WHO Anatomical Therapeutic Chemical (ATC) Classification https://www.whocc.no/copyright_disclaimer/ https://www.whocc.no/atc/ ATC Code https://www.whocc.no/atc_ddd_index/ PubChem https://pubchem.ncbi.nlm.nih.gov Springer Nature https://pubchem.ncbi.nlm.nih.gov/substance/?source=15745&sourceid=15061931-163297434 Thieme Chemistry LICENSE The Thieme Chemistry contribution within PubChem is provided under a CC-BY-NC-ND 4.0 license, unless otherwise stated. https://creativecommons.org/licenses/by-nc-nd/4.0/ https://pubchem.ncbi.nlm.nih.gov/substance/?source=22163&sourceid=15061931-163295758 WHO Model Lists of Essential Medicines https://www.who.int/about/who-we-are/publishing-policies/copyright Oxaliplatin https://list.essentialmeds.org/medicines/101 Medical Subject Headings (MeSH) https://www.nlm.nih.gov/copyright.html Oxaliplatin https://www.ncbi.nlm.nih.gov/mesh/2027910 MeSH Tree http://www.nlm.nih.gov/mesh/meshhome.html Antineoplastic Agents https://www.ncbi.nlm.nih.gov/mesh/68000970 UN Globally Harmonized System of Classification and Labelling of Chemicals (GHS) GHS Classification Tree http://www.unece.org/trans/danger/publi/ghs/ghs_welcome_e.html EPA Substance Registry Services LICENSE https://www.epa.gov/privacy/privacy-act-laws-policies-and-resources EPA SRS List Classification https://sor.epa.gov/sor_internet/registry/substreg/LandingPage.do Show More